This may explain interstitial pneumonia in myelofibrosis and how treatment with JAK2 inhibitors to block the IL-6-mediated JAK2 downstream signaling pathway also blocked the final inflammatory reaction in the lung. This evidence concerns the gene IL6 and myelofibrosis.